Primary Pulmonary Extranodal Marginal Zone Lymphoma/Low Grade B-cell Lymphoma of MALT Type Combined with Well-Differentiated Adenocarcinoma

2010 ◽  
Vol 96 (1) ◽  
pp. 168-171 ◽  
Author(s):  
Aydanur Kargi ◽  
Duygu Gürel ◽  
Atilla Akkoclu ◽  
Aydin Sanli ◽  
Erkan Yilmaz
Keyword(s):  
B Cell ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Marginal Zone Lymphoma ◽  
Low Grade ◽  
Extranodal Marginal Zone Lymphoma ◽  
Well Differentiated

Immunohistochemical Expression of BCL10 and Three Markers in Extranodal Marginal Zone Lymphoma and Other Small B-Cell Lymphomas

2019 ◽  
Vol 152 (Supplement_1) ◽  
pp. S106-S107
Author(s):  
Xiaohong Zhang
Keyword(s):  
B Cell ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Marginal Zone Lymphoma ◽  
Low Grade ◽  
Nuclear Staining ◽  
B Cell Lymphomas ◽  
Extranodal Marginal Zone Lymphoma ◽  
Nuclear Expression

Abstract Extranodal marginal zone lymphoma (EMZL) is a low-grade B-cell lymphoma representing about the third most common non-Hodgkin lymphoma in the Western world. EMZL shows heterogeneous morphological features and expresses no specific immunohistochemical markers except B-cell markers. BCL10 and MALT mutations causing NF-kB pathway activation play an important role in oncogenesis of EMZL. Aberrant nuclear expression of BCL10 is reported in some EMZLs. Nuclear expression of BCL10 has not been well compared between EMZL and other small B-cell lymphomas. The aim of this study is to evaluate the expression of BCL10 and three markers in different small B-cell lymphomas. Tissue microarray blocks and selected tissue blocks, formalin fixed and paraffin embedded, were selected for immunohistochemical (IHC) studies. More than 100 cases of different small B-cell lymphomas include EMZL, small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), and hairy cell leukemia (HCL) in the bone marrow biopsy. Commercially available antibodies from DAKO for BCL-10, IRTA-1, LEF-1, and SOX-11 were used according to the protocol. Immunoreactivity in greater than 20% of the tumor cells was considered positive. BCL-10 nuclear expression occurred mostly in EMZL but also in other small B-cell lymphomas except LPL and HCL. Cytoplasmic expression of IRTA-1 was detected in all cases of EMZL and also in SLL, MCL, and FL cases; it was negative in LPL and HCL. Nuclear expression of LEF-1 was detected mostly in SLL cases, a few cases of MZL, and none of the cases of MCL, FL, LPL, and HCL. Nuclear staining of SOX11 was found in most MCL cases; it was negative in all cases of SLL, EMZL, FL, LPL, and HCL. The IHC markers of BCL-10, IRTA-1, LEF-1, and SOX11 increase our ability to make accurate diagnosis of small B-cell lymphomas.

Marginal Zone Lymphoma (Low-grade B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Type) of Skin and Subcutaneous Tissue

1996 ◽  
Vol 20 (8) ◽  
pp. 1011-1023 ◽  
Author(s):  
Elizabeth M. Bailey ◽  
Judith A. Ferry ◽  
Nancy L. Harris ◽  
Martin C. Mihm ◽  
Joseph O. Jacobson ◽  
...  
Keyword(s):  
B Cell ◽  
Lymphoid Tissue ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
Subcutaneous Tissue ◽  
B Cell Lymphoma ◽  
Marginal Zone Lymphoma ◽  
Tissue Type ◽  
Low Grade

MicroRNA Profiling of Low-Grade and Transformed Nodal Marginal Zone Lymphoma Reveals a Similar Signature Pattern Distinct from Diffuse Large B Cell Lymphoma

2014 ◽  
Vol 133 (2) ◽  
pp. 214-220 ◽  
Author(s):  
Niklas Gebauer ◽  
Christoph Thorns ◽  
Veronica Bernard ◽  
Andrea Senft ◽  
Arne Schillert ◽  
...  
Keyword(s):  
B Cell ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hematologic Malignancies ◽  
Marginal Zone Lymphoma ◽  
Low Grade ◽  
Large B Cell Lymphoma ◽  
Nodal Marginal Zone Lymphoma ◽  
Large B Cell

Background/Aims: As critical post-transcriptional regulators of gene expression, microRNAs are involved in several cellular processes of vital impact including cell growth and apoptosis. Many hematologic malignancies exhibit distinct microRNA signatures. MicroRNA implication in the pathogenesis of nodal marginal zone lymphoma (NMZL), however, remains widely elusive. Methods: Comprehensive morphologic, immunophenotypic and cytogenetic studies were carried out on a cohort of NMZL (n = 30) incorporating indolent as well as transformed MZL. In addition, microRNA signatures were generated, employing a quantitative real-time polymerase chain reaction approach. These were then compared to signatures from cases of diffuse large B cell lymphoma (DLBCL) alongside reactive lymph node controls. Results: While microRNA signatures of low-grade and transformed NMZL did not differ significantly, several microRNAs were differentially expressed between transformed NMZL and DLBCL, hinting at molecularly distinct mechanisms of lymphomagenesis and indicating the biological disparity of transformed NMZL from DLBCL. Conclusion: In the light of the unresolved issue regarding the classification of marginal zone-derived transformed B-cell neoplasms, microRNAs may be a valuable aid in discriminating NMZL from DLBCL. © 2014 S. Karger AG, Basel

Treatment of Extranodal Marginal Zone Lymphoma and Primary Cutaneous B Cell Lymphoma with Rituximab: A Single Institution Experience.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4502-4502
Author(s):  
Robert Chen ◽  
Glen Peterson ◽  
Diana Vucurevich ◽  
Choon-kee Lee ◽  
William Robinson ◽  
...  
Keyword(s):  
B Cell ◽  
Induction Therapy ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
Single Agent ◽  
B Cell Lymphoma ◽  
Marginal Zone Lymphoma ◽  
Extranodal Marginal Zone Lymphoma ◽  
Large B Cell ◽  
Cutaneous B Cell Lymphoma

Abstract Extranodal marginal zone lymphoma is a low grade B cell lymphoma. It comprises about 5% of all non-hodgkin’s lymphoma. They typically present in the lung, thyroid, breast, lacrimal and salivary gland, orbit, and skin. Primary cutaneous B cell lymphoma is an extremely rare form of lymphoma with 3 histological variants: marginal zone, follicular, and diffuse large B cell. In general, they have a high remission rate with overall survival up to 80% at 10 years. At the University of Colorado Health Sciences Center, we have seen ten such cases from July 2005 to July 2007. There is no standard treatement for either extranodal marginal zone lymphoma or primary cutaneous B cell lymphoma, but prior reports have shown long term survival with surgery, radiation, and chemotherapy. Most institutions use radiation therapy as the main modality after excisional biopsy. There is one report by Gitelson et al (leuk lymphoma 2006) using single agent rituximab as the only modality. Out of the ten cases at our institution, six cases were primary cutaneous B cell lymphoma (4 marginal zone, 1 follicular, one diffuse large B cell), and four cases were extranodal marginal zone lymphoma. Four out of six cases of primary cutaneous B cell lymphoma and three out of four of extranodal marginal zone lymphoma was treated with single agent rituximab. Two out of the six cases of primary cutaneous B cell lymphoma and one out of four of extranodal marginal zone lymphoma was treated with radiation. Patients were given induction therapy rituximab at the dose of 375mg/m2 IV weekly x 4 weeks and maintenance therapy at 375 mg/m2 IV every two to three month interval for 8 cycles. 7 patients were given rituximab single agent. All achieved CR (100%) immediately after induction therapy at 1 month. They were also given maintenance treatment. No relapses has occured at the medium follow up of 7 month (3–24 month). Our preliminary result supports the recent report of single agent rituximab. Even though extranodal marginal zone lymphoma is a rare disorder and primary cutaneous B cell lymphoma even more rarer, we feel that a well designed prospective randomized trial would determine the role of rituximab for this disease.

Dural marginal zone lymphoma with massive amyloid deposition: rare low-grade primary central nervous system B-cell lymphoma

2002 ◽  
Vol 96 (2) ◽  
pp. 368-372 ◽  
Author(s):  
Norman L. Lehman ◽  
Dikran S. Horoupian ◽  
Roger A. Warnke ◽  
Uma N. Sundram ◽  
Kendra Peterson ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Amyloid Deposition ◽  
Marginal Zone Lymphoma ◽  
Low Grade ◽  
Solitary Plasmacytoma

✓ The authors report the case of a 63-year-old woman who presented with a primary dural extranodal marginal zone lymphoma (MZL) associated with massive kappa light chain amyloidosis of the meninges. Extranodal MZL is a low-grade B-cell lymphoma that may show variable degrees of plasmacytic differentiation. Like solitary plasmacytoma of soft tissue, which can also be associated with amyloid, extranodal MZL generally responds well to local therapy and has a good prognosis. It is important to distinguish these entities from high-grade primary central nervous system (CNS) B-cell lymphomas and more aggressive and/or widespread, potentially amyloidogenic conditions such as multiple myeloma, lymphoplasmacytoid lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma. To the authors' knowledge this is the first reported case of dural MZL associated with massive meningeal amyloid deposition. Extranodal MZL is a rare low-grade primary CNS B-cell lymphoma that may be associated with amyloidosis. It should be considered in the differential diagnosis of CNS lymphoproliferative lesions and CNS amyloidosis.

Molecular analysis of low grade extranodal marginal zone B-cell lymphoma by alumorph genotyping

2000 ◽  
Vol 118 (4) ◽  
pp. A1385
Author(s):  
Michele De Boni ◽  
Francesco Bertoni ◽  
Roman Mullenbach ◽  
Enrico Roggero ◽  
Angelo Bellumat ◽  
...  
Keyword(s):  
B Cell ◽  
Molecular Analysis ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Low Grade

scholarly journals Extranodal marginal zone non Hodgkin's lymphoma of the lung: A ten-year experience

2011 ◽  
Vol 68 (2) ◽  
pp. 150-154 ◽  
Author(s):  
Violeta Milosevic ◽  
Andrija Bogdanovic ◽  
Snezana Jankovic ◽  
Maja Perunicic-Jovanovic ◽  
Biljana Mihaljevic
Keyword(s):  
B Cell ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
Chop Regimen ◽  
Female Ratio ◽  
Balt Lymphoma

Background/Aim. Bronchus-associated lymphoid tissue (BALT) lymphoma is a rare subtype of low grade marginal zone B cell lymphoma representing 10% of all MALT lymphomas. The purpose of this study was to analyze the outcome of this group of patients comparing prognostic parameters and therapy modalities. Methods. A total of eight patients with BALT lymphoma had diagnosed between January 1998 - April 2008 at the Institute of Hematology, Clinical Center of Serbia, Belgrade, and they were included in this retrospective analysis. Results. Male/female ratio was 2/6, the median age was 64 years (range 37-67 years). Six patients had nonspecific respiratory symptoms and all of them had B symptoms. The patients were seronegative for HIV, HCV and HBsAg. Three patients had Sjogren's syndrome, rheumatoid arthritis and pulmonary tuberculosis, respectively. Seven patients were diagnosed by transbronchial biopsy and an open lung biopsy was done in one patient. Patohistological findings revealed lymphoma of marginal zone B cell lymphoma: CD20+/CD10-/CD5-/CyclinD1- /CD23-/IgM- with Ki-67+<20% of all cells. According to the Ferraro staging system, five patients had localized disease (CS I-IIE) and three had stage IVE; bulky tumor mass had 3 patients. All patients had Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. Five patients received monochemotherapy with chlorambucil and 3 were treated with CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone). A complete response (CR) was achieved in 5 patients and a partial response (PR) in 3 of them, treated with chlorambucil monotherapy and CHOP regimen. All patients were alive during a median follow-up period of 49 months (range 6- 110 months). Three patients relapsed after monochemotherapy into the other extranodal localization. They were treated with CHOP regimen and remained in stable PR. Conclusion. BALT lymphoma tends to be localised disease at the time of diagnosis, responds well to monochemotherapy with chlorambucil and has a favourable prognosis.

Sign in / Sign up

Export Citation Format

Share Document